Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 10/20 | 0.46 |
| ▸ | CA1 | P00915 | 8/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL5040464 | 1.00 | TSHR (0.57) | TSHRTHRBFAAHALDH1A1CA2 | |
| Pentadecane SCHEMBL28155224 | 1.00 | TSHR (0.57) | TSHRTHRBFAAHALDH1A1CA2 | |
| Nonane SCHEMBL6130063 | 1.00 | TSHR (0.57) | TSHRTHRBFAAHALDH1A1CA2 | |
| Tridecane SCHEMBL11411803 | 1.00 | TSHR (0.57) | TSHRTHRBFAAHALDH1A1CA2 | |
| Decane SCHEMBL11411799 | 1.00 | TSHR (0.57) | TSHRTHRBFAAHALDH1A1CA2 | |
| Dodecane SCHEMBL5440620 | 1.00 | TSHR (0.57) | TSHRTHRBFAAHALDH1A1CA2 | |
| Hexadecane SCHEMBL2406023 | 1.00 | TSHR (0.57) | TSHRTHRBFAAHALDH1A1CA2 | |
| Decane SCHEMBL9501386 | 1.00 | TSHR (0.57) | TSHRTHRBFAAHALDH1A1CA2 | |
| Octane SCHEMBL569265 | 1.00 | TSHR (0.57) | TSHRTHRBFAAHALDH1A1CA2 | |
| Hexane SCHEMBL1937959 | 0.96 | TSHR (0.50) | TSHRTHRBFAAHALDH1A1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| CN-1268609-C | Method for making alkanesulphonyl chlorides | ATOFINA (FR) | 2006-08-09 | — | — | CN | disclosed |
| EP-1299402-A4 | PROCESS FOR THE PREPARATION OF HIGHER-ALKANE SULFONYL HALIDES | CHEVRON PHILLIPS CHEMICAL CO (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| CN-1474807-A | Process for the manufacture of alkanesulphonyl chlorides | ���з��ɹ�˾ | 2004-02-11 | — | — | CN | disclosed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | disclosed |
| EP-1299402-A1 | PROCESS FOR THE PREPARATION OF HIGHER-ALKANE SULFONYL HALIDES | Philips Petroleum Company (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1263730-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | Applied Research Systems ARS Holding N.V. (AN) | 2002-12-11 | — | — | EP | disclosed |
| US-6441229-B1 | REACTING A SULFUR COMPOUND AND HALOGEN COMPOUND IN PRESENCE OF PHASE TRANSFER COMPOUND | PHILLIPS PETROLEUM COMPANY | 2002-08-27 | — | — | US | disclosed |
| WO-2002000671-A1 | PROCESS FOR THE PREPARATION OF HIGHER-ALKANE SULFONYL HALIDES | PHILIPS PETROLEUM COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001060798-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-08-23 | — | — | WO | disclosed |
| EP-0805159-A1 | Phosphorus containing alkyl or arylsulphonyl derivatives and method for preparing same | Cytec Canada Inc. (CA) | 1997-11-05 | — | — | EP | disclosed |
| US-4835312-A | Production process of N-substituted amide compounds | MITSUI CHEMICALS, INCORPORATED (JP) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | BAD, BAX, BCL2 | TSHR 3662/4885THRB 2045/4885FAAH 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.